Figure 3.
GC7 enhances gemcitabine sensitivity through inhibition of eIF5A2 in PDAC cells. (A) Western blot analysis for the expression of eIF5A2 in eIF5A2 siRNA-transfected cells. GAPDH was used as an internal control. (B-D) Cell Counting Kit-8 viability assay showing knockdown of eIF5A2 increasing gemcitabine sensitivity of pancreatic cancer cells. (E-G) Following knockdown of eIF5A2 using siRNA, Cell Counting Kit-8 cell viability assays were used to determine the sensitivity of gemcitabine or gemcitabine plus GC7 in pancreatic cancer cells treated with eIF5A2 siRNA.